Author

E. Resnick

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Biophysics· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Approach:deep learning· 1 Organism:mouse· 1 Assay:protein structure· 1 Research Focus:protein structure prediction· 1 Assay:proteomics· 1 Assay:structural biology· 1

Frequent Co-Authors

N. London· 4 shared D. Zaidman· 3 shared F. von DelftiD· 3 shared A. aimon· 2 shared A. Douangamath· 2 shared C. Strain-Damerell· 2 shared D. FearoniD· 2 shared H. Barr· 2 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

N. London

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.

D. Zaidman, P. Gehrtz, M. Filep, D. Fearon, J. Prilusky, S. Duberstein, G. Cohen, D. Owen, E. Resnick, C. Strain-Damerell, P. Lukacik, Covid-Moonshot Consortium, H. Barr, M. A. Walsh, F. von Delft, N. London

The paper introduces a computational pipeline to design irreversible inhibitors, identifying a potent SARS-CoV-2 Mpro inhibitor with low micromolar IC50.

Cell Chemical Biology · Dec 1, 2021Peer-reviewedBiochemistry

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

A. Douangamath, D. Fearon, P. Gehrtz, T. Krojer, P. Lukacik, C. D. Owen, E. Resnick, C. Strain-Damerell, A. aimon, P. Abranyi-Balogh, J. Brandao-Neto, A. Carberry, G. Davison, A. Dias, T. D. Downes, , M. A. Walsh

The paper identifies fragment hits against SARS-CoV-2 main protease using crystallography and mass spectrometry, revealing structural insights for drug design.

bioRxiv · May 27, 2020Biophysics

Sulfopin, a selective covalent inhibitor of Pin1, blocks Myc-driven tumor initiation and growth in vivo

C. Dubiella, B. J. Pinch, D. Zaidman, T. D. Manz, E. Poon, S. He, E. Resnick, E. M. Langer, C. J. Daniel, H.-S. Seo, Y. Chen, S. B. Ficarro, Y. Jamin, X. Lian, S. Kibe, , N. London

Sulfopin, a selective Pin1 inhibitor, reduces tumor initiation and growth in neuroblastoma models by targeting c-Myc pathways.

bioRxiv · Mar 20, 2020 · PreprintCancer Biology

Rapid covalent-probe discovery by electrophile fragment screening

e. resnick, A. Bradley, J. Gan, A. Douangamath, T. Krojer, R. Sethi, A. Aimon, G. Amitai, D. Belini, J. Bennett, M. Fairhead, O. Fedorov, P. P. Geurink, J. Guo, A. Plotnikov, , N. London

This study develops a method for discovering covalent probes using electrophile fragment screening and identifies selective inhibitors for OTUB2 and NUDT7.

bioRxiv · Oct 14, 2018Biochemistry